Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (89)	1/20/2000 7:17:00 PM
From: Richaaard	Read Replies (1) \| Respond to of 286

I noticed the same comparison a couple days ago. Still if you compare the two companies it looks like HYSQ should be worth more. If AFFX is worth $230, then HYSQ could easily add another 50 points to their value. Although AFFX has all their ducks in a row, someone will want to make a run at them at some point. I don't think HYSQ can go it alone buy I'm betting that they will be part of the equation.

To: Edscharp who wrote (89)	1/28/2000 11:20:00 AM
From: nigel bates	Read Replies (1) \| Respond to of 286

>>Interesting Chart<< It depends upon when you start - siliconinvestor.com I was more interested by this - biz.yahoo.com - ``Biochip designs that require a reference sequence, including those that do SNP analysis, may need to secure rights in the reference sequence. The advanced technology Hyseq uses to determine the sequence of any DNA sample may allow our biochips to detect polymorphisms or mutations in patient samples without using gene sequences that may be owned by others, thereby avoiding this pitfall,'" Wonder how much uncertainty is implied by the 'may'. nig